ADD ANI AS A TRUSTED SOURCE
googleads
Menu
Health

Higher oral semaglutide dosage helps in weight loss, blood sugar regulation: Study

Diabetes is a chronic disease that makes controlling blood sugar levels challenging. For many individuals, the problem gets worse with time, making blood sugar management more challenging. Semaglutide is one example of GLP-1 receptor agonist that has provided patients with better control over blood sugar reduction.

ANI Jul 02, 2023 23:40 IST googleads

Representative image (Image source: Pexels)

Washington [US], July 2 (ANI): Diabetes is a chronic disease that makes controlling blood sugar levels challenging. For many individuals, the problem gets worse with time, making blood sugar management more challenging. Semaglutide is one example of GLP-1 receptor agonist that has provided patients with better control over blood sugar reduction.
New information regarding new, higher-dose formulations of oral semaglutide has been provided by John Buse, MD, PhD, the Verne S. Caviness Distinguished Professor of Medicine in the Division of Endocrinology and Metabolism, and a global team of researchers. Their research, which was published in The Lancet, discovered that once-daily oral semaglutide administered at doses of 25 mg and 50 mg was more effective than the lowest dose of 14 mg at reducing blood sugar levels and increasing weight reduction.
"Low doses of GLP-1 receptor agonists are really powerful for reducing A1C, or the average glucose in the blood," said Buse, who is also co-director of the NC Translational and Clinical Sciences Institute, adding, "Whereas, the higher doses that are really good for weight reduction. On average, patients lost eight kilograms (17.5 lbs) at 50 milligrams, which is nearly twice as much weight loss that we saw with the lowest dose."
The new study is in line with other studies, which are pushing for the use of oral GLP-1 receptor agonists as a treatment for obesity. In total, 1,606 participants, who were on average male and 58.2 years of age, participated in the phase three program for regulatory approval.
The participants were randomized into three groups and were asked to take oral semaglutide once a day. Each group took a different dosage of semaglutide, either a 14 mg dosage, a 25 mg dosage, or a 50 mg dosage, for 52 weeks.
Semaglutide also causes weight loss by suppressing appetite. At the end of the 52 weeks, the participants who took 50 mg of oral semaglutide had lost, on average, 17.5 pounds. Those who took 25 mg and 14 mg lost about 14.8 pounds and 10 pounds, respectively. ( ANI)

Get the App

What to Read Next

Health

The truth about ‘Eating for Two’ explained by doctors

The truth about ‘Eating for Two’ explained by doctors

Health experts warn that interpreting the advice literally can lead to excessive calorie intake, unhealthy weight gain and a higher risk of Gestational Diabetes Mellitus (GDM), a condition that affects blood sugar levels during pregnancy.

Read More
Health

High-fat keto diet may boost exercise benefits

High-fat keto diet may boost exercise benefits

A new study suggests that eating more fat rather than less could help the body gain greater benefits from exercise when blood sugar levels are high, offering an unexpected perspective on how diet and physical activity work together to support metabolic health.

Read More
Health

Scientists discover reason high altitude protects against diabete

Scientists discover reason high altitude protects against diabete

Living at high altitude appears to protect against diabetes, and scientists have finally discovered the reason. When oxygen levels drop, red blood cells switch into a new metabolic mode and absorb large amounts of glucose from the blood.

Read More
Health

This gut molecule shows remarkable anti-diabetes power: Study

This gut molecule shows remarkable anti-diabetes power: Study

Researchers revealed that the microbial metabolite TMA can directly block the immune protein IRAK4, reducing inflammation and improving insulin sensitivity.

Read More
Health

Single protein rewires leukemia cells to fuel their growth: Study

Single protein rewires leukemia cells to fuel their growth: Study

Researchers at the UCLA Health Jonsson Comprehensive Cancer Centre have identified a single protein, IGF2BP3, that links these two processes together in leukaemia cells. The protein alters how cells break down sugar, favouring a fast but inefficient energy pathway, while also modifying RNA that helps produce the proteins leukaemia cells need to survive and multiply.

Read More
Home About Us Our Products Advertise Contact Us Terms & Condition Privacy Policy

Copyright © aninews.in | All Rights Reserved.